Trials / Completed
CompletedNCT01404091
A Study of Nociceptin/Orphanin FQ Peptide Receptor Occupancy in Healthy Subjects
Assessment of Nociceptin/Orphanin FQ Peptide Receptor Occupancy After Single Oral Doses of LY2940094 as Measured by Positron Emission Tomography With the Radioligand LY2959530 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- BlackThorn Therapeutics, Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this trial is to conduct an assessment of brain nociceptin/orphanin FQ peptide (NOP) receptor occupancy (RO) in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY2940094 | Administered orally |
Timeline
- Start date
- 2011-07-01
- Primary completion
- 2011-11-01
- Completion
- 2011-11-01
- First posted
- 2011-07-27
- Last updated
- 2017-02-03
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01404091. Inclusion in this directory is not an endorsement.